NCT01423916View on ClinicalTrials.gov

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

March 31, 2012

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

OPC-34712 (4mg)

Arms assigned to this intervention receive 4mg.

DRUG

Moxifloxacin

Arms assigned to this intervention will receive 400mg.

DRUG

OPC-34712 (12mg)

Arms assigned to this intervention receive 12mg.

DRUG

Placebo

OPC-34712 placebo

Trial Locations (8)

19139

Otsuka Investigational Site, Philadelphia

20850

Otsuka Investigational Site, Rockville

33308

Otsuka Investigational Site, Fort Lauderdale

63118

Otsuka Investigational Site, St Louis

66212

Otsuka Investigational Site, Overland Park

78754

Otsuka Investigational Site, Austin

90806

Otsuka Investigational Site, Long Beach

92102

Otsuka Investigational Site, San Diego

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01423916 - Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter